- Merck reported a 2% decrease in total pharmaceutical sales for the third quarter of 2005 compared to 2004, driven by a 5% decrease in US sales and a 2% increase in foreign sales. Volume declined 4% while price increased 1% and foreign exchange increased sales 1%. - For the first nine months of 2005, total sales decreased 5% compared to the same period in 2004. US sales declined 8% due to an 11% decrease in volume while foreign sales declined 2%. - Other income and expenses showed interest income up due to higher investment returns, while interest expense and minority interests also increased.

1. MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
THIRD QUARTER
2005
NET PRODUCT SALES DETAIL (millions of dollars)
3Q `05 vs. 3Q `04
TOTAL TOTAL U.S. U.S. Foreign Foreign
PRODUCT % CHG $ % CHG $ % CHG $
AGGRASTAT 7% 21 N/A - 7% 21
ARCOXIA -8% 56 N/A - -8% 56
CANCIDAS 31% 142 23% 80 43% 62
COZAAR / HYZAAR 6% 751 3% 268 8% 484
CRIXIVAN / STOCRIN 40% 91 9% 9 45% 82
EMEND 60% 22 46% 19 * 4
FOSAMAX - 777 4% 461 -5% 316
INVANZ 51% 25 39% 15 75% 9
MAXALT 10% 92 10% 62 11% 30
PRIMAXIN 12% 182 21% 51 9% 131
PROPECIA - 67 -12% 29 11% 38
PROSCAR 3% 186 8% 98 -1% 88
SINGULAIR 11% 692 10% 490 13% 203
TIMOPTIC / TIMOPTIC XE -9% 35 7% 2 -10% 32
TRUSOPT / COSOPT 13% 156 10% 66 16% 91
VASOTEC / VASERETIC -12% 149 N/A - -12% 149
VIOXX * - * - * -
ZOCOR -14% 1,050 -10% 770 -24% 280
HEPATITIS VACCINES 34% 65 38% 55 25% 10
VIRAL VACCINES 11% 186 11% 171 15% 15
OTHER VACCINES 7% 88 9% 71 - 17
* 100% or over
N/A - Not Applicable
TOTAL SALES: VOLUME, PRICE, EXCHANGE
3Q `05 % CHG. VOL PX FX
TOTAL PHARMACEUTICAL SALES $ 5,416 -2% -4 1 1
U.S. ($ MM) 3,232 -5% -7 3 N/A
Foreign ($ MM) 2,184 2% - -1 2

2. MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
SEPTEMBER YEAR-TO-DATE
2005
NET PRODUCT SALES DETAIL (millions of dollars)
SEPTEMBER YTD `05 vs. SEPTEMBER YTD `04
TOTAL TOTAL U.S. U.S. Foreign Foreign
PRODUCT % CHG $ % CHG $ % CHG $
AGGRASTAT 6% 66 N/A - 6% 66
ARCOXIA 6% 163 N/A - 6% 163
CANCIDAS 39% 413 29% 222 52% 190
COZAAR / HYZAAR 9% 2,255 4% 762 13% 1,493
CRIXIVAN / STOCRIN 34% 258 41% 29 33% 229
EMEND * 59 88% 51 * 8
FOSAMAX 3% 2,402 2% 1,346 5% 1,056
INVANZ 51% 67 36% 42 88% 25
MAXALT 16% 254 19% 163 12% 92
PRIMAXIN 18% 548 45% 156 10% 392
PROPECIA 6% 206 -1% 93 12% 113
PROSCAR 2% 549 1% 271 3% 278
SINGULAIR 14% 2,157 11% 1,472 21% 685
TIMOPTIC / TIMOPTIC XE -10% 103 12% 8 -11% 95
TRUSOPT / COSOPT 12% 450 3% 175 18% 275
VASOTEC / VASERETIC -12% 471 N/A - -12% 471
VIOXX * - * - * -
ZOCOR -15% 3,307 -14% 2,322 -16% 985
HEPATITIS VACCINES -3% 146 -10% 112 25% 34
VIRAL VACCINES 11% 463 9% 417 30% 47
OTHER VACCINES 11% 200 6% 147 29% 53
* 100% or over
N/A - Not Applicable
TOTAL SALES: VOLUME, PRICE, EXCHANGE
YTD `05 % CHG. VOL PX FX
TOTAL PHARMACEUTICAL SALES $ 16,246 -5% -8 1 2
U.S. ($ MM) 9,284 -8% -11 3 N/A
Foreign ($ MM) 6,962 -2% -4 -2 4

3. MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
THIRD QUARTER
2005
OTHER (INCOME)/EXPENSE, NET (millions of dollars)
3Q `05 3Q `04 YTD 2005 YTD 2004
INTEREST INCOME $ (122.3) $ (75.7) $ (314.8) $ (209.8)
INTEREST EXPENSE 99.6 72.4 277.2 216.8
EXCHANGE (GAINS)/LOSSES (7.4) 2.8 (16.5) 9.9
MINORITY INTERESTS 30.9 37.6 91.6 114.0
Other, net (25.5) (41.3) (21.7) (370.9)
TOTAL $ (24.7) $ (4.2) $ 15.8 $ (240.0)
JOINT VENTURE SALES DETAIL (millions of dollars)
All sales reported here are JV sales, presented on a quot;NETquot; basis.
YTD 2005 YTD 2004
Merial 3Q `05 3Q `04
IVOMEC, HEARTGARD, other avermectins $ 124 $ 139 $ 350 $ 335
199 224 614 569
FRONTLINE
133 120 384 343
Biologicals
57 55 172 165
Other Animal Health
$ 513 $ 538 $ 1,520 $ 1,412
TOTAL MERIAL SALES
YTD 2005 YTD 2004
Sanofi Pasteur-MSD 3Q `05 3Q `04
HEPATITIS VACCINES $ 21 $ 20 $ 66 $ 61
VIRAL VACCINES 22 15 61 42
Other Vaccines 256 239 539 483
TOTAL SANOFI-MSD SALES $ 300 $ 274 $ 666 $ 586
Merck / Schering-Plough Collaboration 3Q `05 3Q `04 YTD 2005 YTD 2004
VYTORIN (Worldwide) $ 274 $ 52 $ 673 $ 56
ZETIA (Worldwide) 356 293 1,005 725
TOTAL $ 630 $ 345 $ 1,679 $ 781